Stocks · News reference
Jones Trading has reaffirmed its 'Buy' rating for Rapport Therapeutics, Inc. as of October 21, 2026.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Rapport Therapeutics announced the pricing of its previously proposed public offerings, totaling approximately $175 million in common stock and $150 million in convertible senior notes.
Rapport Therapeutics has commenced separate underwritten public offerings of $200 million in common stock and $150 million in convertible senior notes due 2032.
Goldman Sachs analyst Salveen Richter maintained a 'Buy' rating on Rapport Therapeutics and increased the price target from $62 to $68.